The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.
POLYFUSOR V SODIUM BICARBONATE INTRAVENOUS INFUSION BP 2.74%
NAME OF THE MEDICINAL PRODUCT
Sodium Bicarbonate Infusion BP 2.74%, Polyfusor V
QUALITATIVE AND QUANTITATIVE COMPOSITION Name Sodium Bicarbonate Specification Reference EP %w/v 2.74
PHARMACEUTICAL FORM Intravenous fluid
CLINICAL PARTICULARS Therapeutic indications For the treatment of metabolic acidosis and rapid urine alkalinisation,
Posology and method of administration Adults and Children The volume, strength and rate of infusion will depend upon the requirements of individual patients as perceived by the physician. Administration should be effected cautiously and gradually. In less urgent forms of metabolic acidosis, an average dose for adults and older children is 2-5 mmol of bicarbonate per kg bodyweight, given over 4-8 hours. Subsequent doses of sodium bicarbonate should be adjusted to the individual patient's requirements. It is generally recommended that administration should be initiated with half the calculated dos e which may be adjusted subject to satisfactory blood gas analysis. Elderly Care should be taken to avoid circulatory overload, particularly in patients with cardiac and renal insufficiency.
For intravenous infusion.
Contraindications Intravenous infusions of sodium bicarbonate may be contraindicated in patients with hypertension, impaired renal and cardiac function, pulmonary oedema, respiratory and metabolic alkalosis, hyperventilation, hypernatraemia and eclampsia.
Special warnings and precautions for use Infusion of Polyfusor sodium bicarbonate solutions must be strictly intravenous, since extravasation may lead to tissue necrosis. Administration to patients receiving cardiopulmonary resuscitation may induce pulmonary oedema. Careful attention should be given to avoid possible hypokalaemia. The label states: Do not use unless solution is clear and free from particles.
Interactions with other medicinal products and other forms of interaction Sodium bicarbonate will alkalinise the urine and reduce the urinary excretion of amphetamines, methadone, quinidine and quinine. Sodium bicarbonate will reduce the effectiveness of hexamine compounds, which are only effective as urinary antiseptics in acid urine. The renal excretion of lithium appears to be increased by sodium bicarbonate and this could lead to reduced plasma levels of lithium and impairment of the therapeutic response.
Pregnancy and lactation The safety of Sodium Bicarbonate infusion during pregnancy and lactation has not been assessed, but its use during these periods is not considered to constitute a hazard.
Effects on ability to drive and use machines No adverse effects known.
Undesirable effects Thrombosis of the chosen vein is always a possibility with intravenous infusion.
Overdose Overdose may cause hyperpnoea, nausea and convulsions. Particular care should be paid to administration in the elderly and infants. Over-rapid infusion may lead to hyperosmolarity. In cases of overdosage, the infusion of sodium bicarbonate should be discontinued immediately and metabolic alkalosis corrected by means of administration of 0.9% w/v Sodium Chloride intravenous infusion BP.
Pharmacodynamic properties Sodium Bicarbonate provides a source of bicarbonate ions which will neutralise the relative excess of hydrogen ions present in acidotic conditions
Pharmacokinetic properties No data available.
Preclinical safety data Not available
List of excipients
Water for Injection in bulk Disodium Edetate Carbon Dioxide EP EP EP To 100 0.001 QS
Incompatibilities A number of drugs are incompatible with sodium bicarbonate infusions including; ascorbic acid, adrenaline, benzyl penicillin, calcium chloride, calcium gluconate, calcium salts of drugs, carmustine, cisplatin, codeine, phosphate, corticotrophin, dobutamine, insulin, labetalol, levorphanol, magnesium salts, methadone, morphine sulphate, noradrenaline, oxtetracycline, pethidine, pentobarbitone, procaine, streptomycin, suxamethonium, tetracycline, vancomycin and vitamin B complex with C.
Shelf life 12 months
Special precautions for storage Store at 2 to 25C
Nature and contents of container A sealed semi rigid cylindrical neutral polyethylene container with a 'twist-off' seal at one end and a ring tab at the opposite end.
Instructions for use, handling and disposal Do not dilute before use. Use standard sterile peritoneal dialysis equipment.
MARKETING AUTHORISATION HOLDER
Fresenius Kabi Limited Cestrian Court Eastgate Way Manor Park Runcorn Cheshire WA7 1NT
MARKETING AUTHORISATION NUMBER PL 08828/0012
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION April 1989 / March 1999.
DATE OF REVISION OF TEXT November 1999.
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.